Technology
Health
Pharmaceutical

Tricida

$37.46
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.42 (-1.11%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Tricida and other stocks, options, ETFs, and crypto commission-free!

About

Tricida, Inc. Common Stock, also called Tricida, is a pharmaceutical company, which focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. Read More The company was founded by Gerrit Klaerner and Craig Jon Hawker in 2013 and is headquartered in South San Francisco, CA.

Employees
76
Headquarters
South San Francisco, California
Founded
2013
Market Cap
1.60B
Price-Earnings Ratio
Dividend Yield
Average Volume
244.40K
High Today
$39.24
Low Today
$37.38
Open Price
$38.60
Volume
125.56K
52 Week High
$40.83
52 Week Low
$19.43

Collections

Technology
Health
Pharmaceutical
2018 IPO
US
North America

News

Seeking AlphaMay 12

Tricida, Inc. CEO Gerrit Klaerner on Q1 2019 Results - Earnings Call Transcript

Tricida, Inc. (NASDAQ:TCDA) Q1 2019 Results Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Jackie Cossmon - IR Gerrit Klaerner - CEO, President & Founder Geoff Parker - CFO Conference Call Participants Yuko Oku - JP Morgan Phil Nadeau - Cowen and Company Operator Good day, ladies and gentlemen. Thank you for standing by and welcome to the Tricida First Quarter 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later ,we will condu...

21
The Motley FoolMay 8

Tricida, Inc. (TCDA) Q1 2019 Earnings Call Transcript

Tricida, Inc. (NASDAQ:TCDA) Q1 2019 Earnings Call May 8, 2019, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen. Thank you for standing by and welcome to the Tricida first quarter 2019 financial results conference call. At this time, all participants on a listen-only mode. Later, we'll conduct a question-and-answer session, instruction for that time. If you should require any assistance in the call, please pres...

22
Yahoo FinanceMay 8

Tricida Announces First Quarter 2019 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Webcast Today at 4:30 pm Eastern Time Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today financial results for the three months ended March 31, 2019 and provided an update on key initiatives. Recent Highlights Completed a follow-...

11

Earnings

-$0.89
-$0.79
-$0.70
-$0.60
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.